title: [Why and how correct calcidiol deficiency in haemodialysis patients?].
abstract: The plasma concentration of 25(OH) D - calcidiol - is low in most of stage 5 renal patients. Due to the lack of renal 1alpha-hydroxylase, no supplementation is recommended. However, calcidiol also displays many extraosseous beneficial antiproliferative effects. It may be useful to correct its deficiency in dialysis patients. The efficacy of an oral supplementation for 6 months with ergocalciferol, (Sterogyl), was evaluated in a monocentric cohort of 107 prevalent hemodialysis patients. Plasma levels of 25(OH) D, parathormone, total and ionized calcium, phosphates, were measured at month 0, 3 and 6 in all patients and plasma levels of 1-25(OH) D at month 0 and 6 in 38 patients with the lowest 25(OH) D levels at baseline. Patients were divided into four groups according to their initial 25(OH) D plasma levels and received ergocalciferol supplementation in accordance to the KDOQI Guidelines for stage 3 and 4 renal patients.
  
  
  RESULTS
  101/107 patients display low levels of 25(OH) D at baseline: mean 11.8+/-11.6 microg/l (normal> 30 microg/l). At the end of the initial three months correction period, the plasma levels of 25(OH) D rose significantly. However, only 60% of patients reach a normal plasma concentration of calcidiol with the highest - 600,000UI - ergocalciferol cumulative dosage. At the end of the three months maintenance period, plasma 25(OH) D concentrations fell in all patients. No significant change was observed in parathormone, calcium, phosphates and 1-25(OH) D plasma levels. There was no hypercalcemic episode.
  
  
  CONCLUSIONS
  KDOQI ergocalciferol recommended doses for stages 3 and 4 renal patients did not correct calcidiol deficiency in hemodialysis patients. New prospective studies are required for defining the modalities of an efficient vitamin D supplementation with ergocalciferol or cholecalciferol.
authors: Service de néphrologie et transplantation, hôpital Maison-Blanche, CHU de Reims, 51100 Reims, France. hmaheut@chu-reims.fr
authors: Hervé
authors: H
authors: Maheut
authors: Fabien
authors: F
authors: Chevriot
authors: Hélène
authors: H
authors: Marty
authors: Sylvie
authors: S
authors: Lavaud
authors: Isabelle
authors: I
authors: Kazes
authors: Jacques
authors: J
authors: Chanard
authors: Philippe
authors: P
authors: Rieu
mesh_terms: D000368:Aged; D001361:Avitaminosis / Q000097:blood / Q000188:drug therapy*; D002112:Calcifediol / Q000097:blood / Q000172:deficiency*; D004872:Ergocalciferols / Q000627:therapeutic use*; D006801:Humans; D006435:Renal Dialysis; D014815:Vitamins / Q000627:therapeutic use*
chemical_list: D004872:Ergocalciferols; D014815:Vitamins; D002112:Calcifediol